Nepal Bets on Local Drug Production as It Moves to Make 25 Essential Medicines at Home

Nepal is taking a bigger step toward pharmaceutical self-reliance. Finance Minister Dr. Swarnim Wagle has announced that the government will empower Nepal Drugs Limited to produce 25 types of essential medicines locally, including drugs that are supplied free of cost by the state.

The announcement, made during the presentation of the annual budget for fiscal year 2083/84, signals a renewed push to strengthen domestic medicine manufacturing and reduce the country’s reliance on imported pharmaceuticals.

Why this move matters

The new plan is important because essential medicines are the backbone of public health systems. By producing more of them inside Nepal, the government aims to improve supply stability, support affordability, and reduce exposure to global supply chain disruptions.

This is also a strategic industrial policy move. Nepal has long depended heavily on imported medicine, and expanding local production could help build a stronger domestic pharmaceutical sector over time.

What Nepal Drugs Limited is expected to produce

According to the news summary, the 25 medicines include products that are already part of the free medicine program offered by the state. That suggests the government is focusing first on high-demand, widely used treatments that matter directly to public health access.

The broader context is that Nepal’s essential medicines policy has long aimed to increase domestic production. Prior research and policy documents show the country has pursued self-reliance in essential drugs for years, with government goals historically centered on manufacturing a large share of essential formulations at home.

A wider push for self-reliance

Nepal’s pharmaceutical sector already has some domestic production capacity, but the market still depends significantly on imports. Industry and policy reports indicate that the country has made progress in producing many medicines locally, yet import dependence remains a major issue, especially for a large share of market demand.

That is why expanding production at a state-owned company like Nepal Drugs Limited matters beyond the immediate list of medicines. It could help create a stronger public-sector benchmark for local manufacturing, improve availability of essential drugs, and potentially encourage broader industrial growth in the sector.

The public health angle

Essential medicines are not just an industrial issue - they are a healthcare access issue. When the state can source more of these medicines domestically, it may be better positioned to ensure consistent supply to public facilities and reduce pressure from price fluctuations in international markets.

Reports about Nepal’s health system have also highlighted challenges with medicine quality, storage, and availability in public facilities. A stronger domestic production system may help address some of these weaknesses if it is paired with effective regulation and quality control.

What to watch next

The key question now is execution. The success of this plan will depend on whether Nepal Drugs Limited has the capacity, technology, raw materials, and regulatory support needed to produce the medicines at scale and on time.

If the government follows through, the move could become one of Nepal’s more practical health-sector reforms: a direct effort to make essential medicine more secure, more local, and potentially more affordable for the people who need it most.